Macromolecular mechanisms of sputum inhibition of tobramycin activity.
about
Inhaled anti-infective chemotherapy for respiratory tract infections: successes, challenges and the road aheadTobramycin Inhalation Powder (TIP): An Efficient Treatment Strategy for the Management of Chronic Pseudomonas Aeruginosa Infection in Cystic FibrosisActivity and interactions of liposomal antibiotics in presence of polyanions and sputum of patients with cystic fibrosisUnfractionated heparin reduces the elasticity of sputum from patients with cystic fibrosis.Fosfomycin/tobramycin for inhalation in patients with cystic fibrosis with pseudomonas airway infection.Potential novel therapeutic strategies in cystic fibrosis: antimicrobial and anti-biofilm activity of natural and designed α-helical peptides against Staphylococcus aureus, Pseudomonas aeruginosa, and Stenotrophomonas maltophilia.Revealing the dynamics of polymicrobial infections: implications for antibiotic therapy.Enhanced in vitro formation and antibiotic resistance of nonattached Pseudomonas aeruginosa aggregates through incorporation of neutrophil products.Aeromonas punctata derived depolymerase improves susceptibility of Klebsiella pneumoniae biofilm to gentamicin.Mucin Binding Reduces Colistin Antimicrobial Activity.Filamentous Bacteriophage Promote Biofilm Assembly and Function.In vitro activities of a novel nanoemulsion against Burkholderia and other multidrug-resistant cystic fibrosis-associated bacterial species.Inhaled antibiotics for gram-negative respiratory infections.Combating biofilms.Inhaled aztreonam lysine for cystic fibrosis pulmonary disease-related outcomes.Targeting quorum sensing in Pseudomonas aeruginosa biofilms: current and emerging inhibitors.Pseudomonas aeruginosa biofilm infections: from molecular biofilm biology to new treatment possibilities.Tobramycin inhalation powder: an efficient and efficacious therapy for the treatment of Pseudomonas aeruginosa infection in cystic fibrosis.Polyanion-tobramycin nanocomplexes into functional microparticles for the treatment of Pseudomonas aeruginosa infections in cystic fibrosis.The particle in the spider's web: transport through biological hydrogels.Cathelicidin peptides inhibit multiply antibiotic-resistant pathogens from patients with cystic fibrosis.P-113D, an antimicrobial peptide active against Pseudomonas aeruginosa, retains activity in the presence of sputum from cystic fibrosis patients.Transport of nanoparticles in cystic fibrosis sputum and bacterial biofilms by single-particle tracking microscopy.Sputum tobramycin concentrations in cystic fibrosis patients with repeated administration of inhaled tobramycin.Extracellular DNA shields against aminoglycosides in Pseudomonas aeruginosa biofilms.Bacterial Biofilm Control by Perturbation of Bacterial Signaling Processes.Resistance of the antibacterial agent ceragenin CSA-13 to inactivation by DNA or F-actin and its activity in cystic fibrosis sputum.Extracellular DNA Acidifies Biofilms and Induces Aminoglycoside Resistance in Pseudomonas aeruginosa.Fosfomycin enhances the active transport of tobramycin in Pseudomonas aeruginosaReal-world challenges to the practice of evidence-based medicine.Differential protection from tobramycin by extracellular polymeric substances from Acinetobacter baumannii and Staphylococcus aureus biofilms.Efficacy of liposomal bismuth-ethanedithiol-loaded tobramycin after intratracheal administration in rats with pulmonary Pseudomonas aeruginosa infection.In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis.Antibacterial activities of a fosfomycin/tobramycin combination: a novel inhaled antibiotic for bronchiectasis.Importance of DNase and alginate lyase for enhancing free and liposome encapsulated aminoglycoside activity against Pseudomonas aeruginosa.Distribution of DNA and alginate in purulent cystic fibrosis sputum: implications to pulmonary targeting strategies.Stability and activity in sputum of G10KHc, a potent anti-Pseudomonas antimicrobial peptide.A phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infection.The Rationale and Evidence for Use of Inhaled Antibiotics to Control Pseudomonas aeruginosa Infection in Non-cystic Fibrosis Bronchiectasis.Sputum Active Polymyxin Lipopeptides: Activity against Cystic Fibrosis Pseudomonas aeruginosa Isolates and Their Interactions with Sputum Biomolecules.
P2860
Q26822988-A0D228C7-882C-4EC6-BAA6-1EEF656B1FCAQ26829604-50C64B46-7AD2-4865-83D0-7EE07C9D9A9BQ28475562-FB715BF4-3DF1-4580-8EC1-5F6541A7C60FQ33298018-00ED3EF0-2FC6-4CAA-B529-647DD1BAEDC1Q34233774-6A5FD287-7DAD-430E-B61E-70409EA6AE38Q34348146-EF5071AD-D5BD-4695-8BD4-C9F88797BA3DQ34554419-42D0EF3A-E990-4DB9-8FAA-A42FDCF871A8Q34596738-15901FBD-DE59-40C2-8558-65394F1762B3Q35660517-19A023C7-B766-49AF-ACB4-E185F49C4D8FQ36076096-78B83D00-20F2-46AE-8165-DFDD0EC2A57EQ36299807-4E6183E9-981A-4D54-9510-FF3CCDA34566Q37032826-1430E0A8-7719-4EC8-A6BE-3F3F1E6433CEQ37937558-F749B7F2-F1AA-4CAB-9BC4-68E261A37DACQ37953971-5FB4FF67-6543-4CF1-A0FF-8CF4D3074091Q38024091-7D7090C2-93E0-4B9D-9110-A543F1DD5B58Q38120561-7FE8AFE9-796F-41A0-8A12-76C179EDAE3BQ38268531-0BEE1D18-B447-48E4-A5CD-3FF890D4EE77Q38358856-F8128651-5930-4209-B8B2-A3F40C0C9B67Q38729352-798E0405-4969-4027-B4A1-0408B12983F7Q39350747-EE9EF6FA-AB5D-4869-BE15-417B7B44D551Q39478540-F4A8E656-7307-4CBC-91F5-104CFC28998CQ39479122-1E7D8165-A205-4752-AE8F-68DD76421D4FQ39542270-B9A091A2-AB02-4A35-B1B3-62E318D55258Q39713307-71DCD93A-9C3F-4123-A928-3D9C2AFD714AQ40005043-F778E167-4535-45A7-9C83-3BB4D1D18439Q40049388-E2FBF217-952C-4B2D-931B-38C8B52ACB82Q40116758-9ACB5BE6-4C0B-4F91-B8D3-9932F91E7503Q40339646-6975386F-BA1A-4F89-8E64-F06868E8C942Q41812492-F6F937D9-B89A-48F1-B193-FF534F7AC41AQ41834845-EFB62E1C-8D08-4E13-9D73-C24CE7FF0E30Q41856349-577A5E99-8807-4705-A822-F59D56F70948Q41907356-C037CB2D-A730-4871-AE7B-8168CD7EE710Q42017846-959167EB-1487-48BF-8DA8-D12336F03B8EQ42550334-2293500D-21C6-439F-ACB3-05D8CD104AD8Q44877341-8397651B-3D68-4189-A34C-5CE80A2E4FD9Q45880451-8B60EFC4-1775-4F8A-972C-C4F508C7D34DQ46619725-1BEC71BE-74D1-4C7F-8581-505B8B1F98ABQ46880557-197E15F7-EBB8-4BC3-B977-40E1880A8E11Q47730320-031AE180-DA2C-470B-BF0E-960E4C5FF5FEQ51736541-E64246DB-9096-44DB-B802-F4F8C67DBF6A
P2860
Macromolecular mechanisms of sputum inhibition of tobramycin activity.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年学术文章
@wuu
1995年学术文章
@zh-cn
1995年学术文章
@zh-hans
1995年学术文章
@zh-my
1995年学术文章
@zh-sg
1995年學術文章
@yue
1995年學術文章
@zh
1995年學術文章
@zh-hant
name
Macromolecular mechanisms of sputum inhibition of tobramycin activity.
@en
Macromolecular mechanisms of sputum inhibition of tobramycin activity.
@nl
type
label
Macromolecular mechanisms of sputum inhibition of tobramycin activity.
@en
Macromolecular mechanisms of sputum inhibition of tobramycin activity.
@nl
prefLabel
Macromolecular mechanisms of sputum inhibition of tobramycin activity.
@en
Macromolecular mechanisms of sputum inhibition of tobramycin activity.
@nl
P2093
P2860
P356
P1476
Macromolecular mechanisms of sputum inhibition of tobramycin activity.
@en
P2093
P2860
P356
10.1128/AAC.39.1.34
P407
P577
1995-01-01T00:00:00Z